The Latest Breaking News from Danaher

With Danaher gearing up to release its third-quarter earnings later this month, analysts expect double-digit earnings decline.

Danaher recently underperformed the healthcare sector, but Wall Street analysts are moderately bullish about the stock’s prospects.

Danaher has lagged behind the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Danaher stock flirted with a breakout Tuesday on the back of its unexpectedly strong sales from its molecular testing services.

Danaher shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +1.20%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.51%. US stock indexes closed moderately higher on Tuesday, with the Dow Jones Industrials climbing...

PulteGroup received an added data boost, Danaher's markets are looking up, and JetBlue collapses, despite a not-as-bad-as-feared loss.

In the specialized field of spinoff companies, Veralto emerges as a prime investment opportunity, stemming from its recent spinoff from Danaher Corporation.

With rapidly increasing healthcare demands, numerous technological breakthroughs, and advanced research and development, the medical industry is well-poised for remarkable growth and profitability. As medical companies Danaher (DHR) and Stryker (SYK) gear to report their fourth-quarter earnings tomorrow, let’s determine if these stocks are ideal buys ahead of earnings….

Danaher Corp, the biotech/life sciences products firm, has had unusual call options activity today. It highlights the value of shorting out-of-the-money "covered calls" in DHR stock as an income play.

PE firms need CEOs to run their fast-growing portfolio companies and are draining succession talent from public companies.